News

Pharmather has filed a request to meet with the U.S. Food and Drug Administration (FDA) to determine next best steps in the clinical development of ketamine to treat the levodopa-induced dyskinesia associated with Parkinson’s disease. The filing is in preparation for a proposed Phase 2 clinical study of ketamine,…

Eli Lilly has announced an agreement to acquire biotechnology company Prevail Therapeutics. Following the deal, Lilly plans to create a gene therapy program for people with neurodegenerative diseases, including Parkinson’s. “The acquisition of Prevail will bring critical technology and highly skilled teams to complement our existing expertise at Lilly,…

The Michael J. Fox Foundation (MJFF) has awarded a grant to Sengenics for work in identifying new autoantibody signatures in people at high risk of Parkinson’s disease, and to investigate these proteins’ role in the disease’s course. “We are delighted to have been awarded this prestigious Michael J. Fox Foundation research…

Most people who undergo genetic testing and counseling related to Parkinson’s disease are satisfied with their experience and feel no substantially adverse psychological effects, a study reported. However, its findings also indicated that people with diagnosed Parkinson’s, or in whom Parkinson’s-linked mutations are identified, are more likely to be…

A state-of-the-art digital technology that targets different brain areas during specific physiotherapy strategies used to measure walking and brain activity changes in Parkinson’s disease patients, is being developed by researchers at Northumbria University, England. Understanding these changes may help target and treat walking problems in these patients. Difficulties with movement, including walking,…

Changes in how brainwaves synchronize, known to occur in people with Parkinson’s disease, originate from distinct nerve cell networks in multiple brain regions involved in motor control, a study found.  Applying electrical stimulation to correct the abnormally coupled brainwaves may benefit…

Researchers from the Texas Woman’s University will investigate the benefits of equine-assisted therapy, known as EAT, in elder adults with Parkinson’s disease, with the help of a research grant from the Human Animal Bond Research Institute (HABRI). A non-profit organization, HABRI hopes to advance…

For the first time, researchers have confirmed the existence of a system that helps to clear waste from the brain in mammals other than rodents. The findings may hold implications for the treatment of neurodegenerative diseases, like Parkinson’s and Azlheimer’s, researchers said. Results of the research were shared…

Participants are now being recruited for several clinical trials testing investigational treatments for Parkinson’s disease, The Michael J. Fox Foundation (MJFF) announced. Clinical trials are well-designed experiments conducted on human participants. Since such trials actually test a treatment in people, these studies are essential for understanding whether a given…

Delivering an alpha-synuclein-targeting molecule, called ASO4, in tiny fatty vesicles reduced toxic alpha-synuclein clumps and dopaminergic neuron loss — two main hallmarks of Parkinson’s disease — and lessened motor impairments in a mouse model of the disease. Results of the study add to previous findings suggesting that these…